Selection of Itamar's WatchPAT home sleep apnea diagnostic system underscores the importance and significance of understanding sleep disorders to prevent and manage risk of heart disease and stroke
Recognition that unique biological data collected from WatchPAT will be a valuable addition to the Project 10K database and its predictive medicine goals
“The choice of Itamar Medical’s advanced WatchPAT system for the diagnosis of sleep apnea emphasizes the relationship and significance that the medical and public health communities attribute to the sleep dimension and the impact of sleep quality on the risks of morbidity and heart disease in particular,” said
As part of the project, Itamar will provide 150,000 WatchPAT tests for the diagnosis and monitoring of sleep apnea. Each subject will undergo a WatchPAT Sleep Apnea diagnostic test once every two years. The WatchPAT’s signals and test results will be used by the team of researchers in developing advanced artificial intelligence-based prediction tools that will reveal connections between sleep apnea and other health conditions that have not previously been known or understood.
Prof.
Additional information about Project 10K is available at http://www.weizmann.ac.il/sites/Project10K/.
About
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss potential WatchPAT test results and the impact these results may have on developing products and the impact of these products, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of our control and actual results, expressed or implied by such forward-looking statements, could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by us in reports filed with, or furnished to, the
The contents of any website of hyperlinks mentioned in this press release are for informational purposes only and the contents thereof are not part of this press release nor is it incorporated herein by reference.
Itamar Medical Company Contact
Chief Financial Officer
Phone: +972-4-617-7700
bshy@itamar-medical.com
Itamar Medical Investor Relations Contact (
Phone: 212-867-1762
david.carey@finnpartners.com
2020 GlobeNewswire, Inc., source